pharma
1 article
Biogen and Denali's LRRK2 Inhibitor Flops in Phase II Parkinson'sAnother genetic-targeted Parkinson's therapy crashes in Phase II, reinforcing how brutally hard neurodegeneration drug development ...
1 article
Biogen and Denali's LRRK2 Inhibitor Flops in Phase II Parkinson'sAnother genetic-targeted Parkinson's therapy crashes in Phase II, reinforcing how brutally hard neurodegeneration drug development ...